BHT3009
/ Bayhill Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
January 10, 2012
Evolution of MS lesions to black holes under DNA vaccine treatment
(J Neurol)
- P2, N=155; NCT00382629; New lesions at weeks 8 and 16 were tracked at week 48 and those appearing as T1-hypointense were classified as PBH; Patients receiving 0.5mg BHT-3009 showed a reduced risk of PBH with higher antibody levels compared to placebo (p less than 0.01)
Retrospective analysis • Multiple Sclerosis
1 to 1
Of
1
Go to page
1